Immunohistochemistry â€“ Microarray Analysis of Patients with Peritoneal Metastases of Appendiceal or Colorectal Origin by Danielle E. Green et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 05 January 2015
doi: 10.3389/fsurg.2014.00050
Immunohistochemistry – microarray analysis of patients
with peritoneal metastases of appendiceal or colorectal
origin
Danielle E. Green1,ThejusT. Jayakrishnan1, Michael Hwang1, Sam G. Pappas2,T. Clark Gamblin1 and
Kiran K.Turaga1*
1 Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA
2 Division of Surgical Oncology, Department of Surgery, Loyola University Medical Center, Maywood, IL, USA
Edited by:
Orhan Alimoglu, Istanbul Medeniyet
University, Turkey
Reviewed by:
Ulf Gunnarsson, Karolinska Institutet,
Sweden
Juan Manuel Suárez-Grau, Hospital
Riotinto, Spain
Paul Willemsen, Ziekenhuisnetwerk
Antwerpen (ZNA), Belgium
*Correspondence:
Kiran K. Turaga, Division of Surgical
Oncology, Department of Surgery,
Medical College of Wisconsin,
9200W Wisconsin Avenue,
Milwaukee, WI 53226, USA
e-mail: kturaga@mcw.edu
Background: The value of immunohistochemistry (IHC)-microarray analysis of pathologi-
cal specimens in the management of patients is controversial, although preliminary data
suggest potential benefit. We describe the characteristics of patients undergoing a com-
mercially available IHC-microarray method in patients with peritoneal metastases (PM) and
the feasibility of this technique in this population.
Methods:We retrospectively analyzed consecutive patients with pathologically confirmed
PM from appendiceal or colorectal primary who underwent Caris Molecular Intelligence™
testing. IHC, microarray, FISH, and mutational analysis were included and stratified by Peri-
toneal Carcinomatosis Index (PCI) score, histology, and treatment characteristics. Statistical
analysis was performed using non-parametric tests.
Results: Our study included 5 patients with appendiceal and 11 with colorectal PM. The
median age of patients was 51 (IQR 39–65) years, with 11 (68%) female. The median PCI
score of the patients was 17 (IQR 10–25). Hyperthermic intra-peritoneal chemoperfusion
was performed in 4 (80%) patients with appendiceal primary tumors and 4 (36%) with
colorectal primary. KRAS mutations were encountered in 40% of appendiceal vs. 30% col-
orectal tumors, while BRAF mutations were seen in 40% of colorectal PM and none of the
patients with appendiceal PM (p=0.06). IHC biomarker expression was not significantly
different between the two primaries. Sufficient tumor for microarray analysis was found
in 44% (n=7) patients, which was not associated with previous use of chemotherapy
(p> 0.20 for 5-FU/LV, Irinotecan and Oxaliplatin).
Conclusion: In a small sample of patients with PM, the feasibility and results of IHC-
microarray staining based on a commercially available test is reported. The apparent high
incidence of the BRAF mutation in patients with PM may potentially offer opportunities for
novel therapeutics and suggest that IHC-microarray is a method that can be used in this
population.
Keywords: colorectal neoplasms, appendiceal neoplasms, peritoneal neoplasms, microarray analysis,
immunohistochemistry, DNA mutational analysis
INTRODUCTION
Predictive and prognostic biomarkers have been studied in dif-
ferent cancers with the aim of developing personalized medicine
for patients (1, 2). The role of immunohistochemistry (IHC)-
microarray analysis of pathological specimens in this paradigm
is currently being investigated, and preliminary data do suggest
potential utility (3, 4). Few studies have examined the value of
gene expression and molecular profiling of specimens in the set-
ting of peritoneal metastases (PM) (5–7). However, the role of
IHC-microarray analysis of specimens from PM of appendiceal or
colorectal origin is not well elucidated.
Gene expression profiling has pointed toward phenotypic clus-
tering with distinct survival outcomes for patients with PM (8).
Vascular endothelial growth factor (VEGF) has been suggested as
a potential prognostic marker for patients with PM from muci-
nous adenocarcinoma originating in the appendix or colon (9, 10).
In colorectal cancer, there is evidence to support the association
of malignant transformation and peritoneal dissemination with
BRAF/KRAS mutations (11–14). Genes in the RAF family encode
kinases regulated by the Ras pathway and mediate cell responses
to growth signals. As such, BRAF is seen as a gene downstream
from KRAS. Interestingly, BRAF and KRAS mutations have been
observed to be mutually exclusive even though they exert equal
effects on tumorigenesis (15).
Also important in colorectal cancer, cyclooxygenase-2 (COX-2)
is an enzyme that is upregulated in colorectal cancer (16, 17).
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COX-2 inhibitors, like aspirin, have a protective effect on the devel-
opment of colorectal cancer, and have been shown to improve
survival in COX-2 overexpressing tumors (18, 19). The therapeu-
tic value of COX-2 inhibition in appendiceal tumors is not clearly
defined although studies have demonstrated increased expression
(20).
Demonstration of the clinical utility of molecular profiling in
guiding successful systemic therapy have resulted in a surge in the
use of commercial molecular profiling services (21). The purpose
of this study was to assess the feasibility of routine IHC-microarray
and mutational analysis of patients with PM of appendiceal and
colorectal primaries using a commercially available molecular
profiling service. This is important in the context of mucinous
contents of these tumors that could impact the sampling and
analysis.
MATERIALS AND METHODS
SUBJECTS
A retrospective chart review with Institutional Review Board (IRB)
approval was performed to identify all patients that had appen-
diceal or colorectal primaries with PM that also had tissue biopsies
for molecular profiling (Caris Molecular Intelligence™) sent to
Caris Life Sciences lab (Phoenix, AZ, USA), which is a central Clin-
ical Laboratory Improvement Amendments-certified laboratory.
Additional demographics, histology, surgery, and treatment details
were collected from medical records. Resultant biomarker data
were then stratified by Peritoneal Carcinomatosis Index (PCI),
histology, and treatment characteristics. All patients were treated
at the regional cancer therapy program at the Medical College of
Wisconsin (MCW) between April 2008 and June 2012. Patients
with insufficient tissue for molecular profiling to be performed or
having primaries other than the colon or appendix were excluded
from the study.
PATIENT SAMPLES
Our standard practice for patients with high grade appendiceal
adenocarcinoma or colorectal carcinomatosis is to evaluate the
patients with a staging laparoscopy after four to six cycles of sys-
temic chemotherapy. Biopsies for pathological and biochemical
analysis were obtained during laparoscopy and shipped to Caris
lab using standard protocol aimed to provide theranostic informa-
tion (21). Sufficiency of the sample for biochemical analysis (Caris
Molecular Intelligence™) was determined at the lab. Primary anti-
bodies used for IHC are COX-2 (SP21), ERCC1 (8F1), PTEN
(6H2.1), SPARC monoclonal (122511), SPARC polyclonal (poly-
clonal), TOP2A (3F6), TOPO1 (1D6), TS (TS106/4H4B1), and
RRM1 (polyclonal). Avidin-biotin systems and polymer-based,
biotin-free systems were used for detection of the antibodies. The
chromogenic reporter, 3,3′-diaminobenzidine (DAB), was used to
allow for a colorimetric visualization of the antibody yielding a
brown stain that can be analyzed with a light microscope. The
intensity of the staining was scored as 0, 1+, 2+, or 3+, and the
percentage of staining cells was scored as 0–100% by a board-
certified pathologist. Thresholds to determine patient benefit to
therapeutic agents included the following: negative TS, staining
smaller than or equal to 1+, 25%; negative ERCC1, percentage of
staining smaller than or equal to 25%; high TOP2A, percentage
of staining >10%. DNA microarray was performed on total RNA
extracted from tumor tissue and was converted to cDNA. This
cDNA sample was then subjected to a whole genome microar-
ray analysis using Illumina cDNA-mediated annealing, selection,
extension, and ligation (DASL) process with the HumanHT-12
v4 beadChip (Illumina Inc., San Diego, CA, USA). After direct
hybridization and scanning of the bead array, the expression of
a subset of 88 transcripts were then compared to tissue-specific
normal control pools and the statistical significance of the differ-
ence between the patient tumor sample and control is determined.
Direct sequence analysis was performed on genomic DNA isolated
from a tumor sample using custom primers designed to flank,
amplify and sequence codons 12 and 13 in exon 2 and codon 61
in exon 3 of the KRAS gene, and codons 464–469 of exon 11 and
codon 600 of exon 15 in the BRAF gene.
TREATMENT
Following laparoscopic evaluation, patients were classified as
extensive disease for exclusion from Cytoreductive Surgery with
hyperthermic intra-peritoneal chemoperfusion (CRS+HIPEC)
for PCI scores higher than 11 for gastric cancer, and 19 for col-
orectal and non-gastric primaries. After cytoreduction,HIPEC was
performed using the closed technique and dosing of therapy was
based on standard published consensus guidelines (22).
STATISTICAL ANALYSIS
Statistical calculations were performed using STATA software ver-
sion 12.1 (StataCorp, TX, USA). Non-parametric methods of
Kruskal Wallis and chi-square tests were employed. Survival out-
comes were explored using Cox proportional hazards model.
Alpha was fixed at 0.05 for statistical significance.
RESULTS
The baseline characteristics and survival of the subjects are
described in Table 1. Of the 16 patients, 11 had colon primaries
and 5 had appendix primaries. Biopsies were sufficient in size for
IHC to be performed on 16 patient samples vs. 7 for microarray.
Patients with colon cancer were twice as likely to undergo neoad-
juvant chemotherapy vs. those with appendiceal cancer that were
twice as likely to undergo HIPEC upfront.
IMMUNOHISTOCHEMISTRY (IHC)
Immunohistochemistry results are described in Table 2. Differ-
ences in percent staining or staining intensity were not significantly
different between the two cancer primaries (p-value= 0.20). Of
note, COX-2 was not differently expressed between the two
groups with 80% staining in colorectal vs. 100% in appendiceal
(p-value= 0.52).
MUTATIONAL ANALYSIS
The results of mutational analysis (n= 15) are represented in
Figure 1. Patients with appendiceal primary were all BRAF wild
type, but were split between KRAS wild type (40%) and KRAS
mutant (40%). The analysis was reported as“indeterminate KRAS”
for 1 patient (20%). Patients with colon primary had more
variation in their mutations with the most common mutation
being BRAF mutated with KRAS wild type (40%) vs. 20% with
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Table 1 | Baseline characteristics and survival of colon and appendix
cancer patients included in the study.
All patients
(n=16)
Colon
(n=11)
Appendix
(n=5)
p-value
Age (median and
range in years)
51 (42–60) 51 (38–72) 51 (40–56) 0.42
Female 11 (69%) 8 (73%) 3 (60%) 1.00
AJCC6 T-stage T4 11 (69%) 8 (73%) 3 (60%) 1.00
Neoadjuvant
chemotherapy
11 (69%) 9 (82%) 2 (40%) 0.24
PCI score (median
and range)
17 (13–26) 17 (8–27) 17 (12–20) 0.82
CRS+HIPEC 8 (50%) 4 (36%) 4 (80%) 0.28
Median
survival (months)
– 30 60 0.50
AJCC, American Joint Committee on Cancer; PCI, Peritoneal Carcinomatosis
Index; CRS+HIPEC, cytoreductive surgery with hyperthermic intra-peritoneal
chemoperfusion.
Table 2 | Immunohistochemistry (IHC) findings stratified by
histological subtype.
Biomarker (IHC) Colon (N =11) Appendix (N =5) p-value
COX-2 80% 100% 0.52
ERCC1 100% 100% 1.00
PTEN 100% 100% 1.00
SPARC 36% 20% 1.00
TOP2A 100% 80% 0.31
TOPO1 100% 100% 1.00
TS 82% 80% 1.00
COX-2, cyclooxygenase-2; ERCC1, excision repair cross-complementing rodent
repair deficiency, complementation group 1; PTEN, phosphatase and tensin
homolog; SPARC, secreted protein acidic cysteine-rich; TOP2A, topoisomerase
(DNA) 2 alpha; TOPO1, topoisomerase (DNA) 1; TS, thymidylate synthase.
BRAF wild type–KRAS wild type vs. 20% BRAF wild type–KRAS
mutant. Of two patients who did not have BRAF mutation analysis
performed, one was KRAS mutant.
SURVIVAL
The results of survival analysis are described in Table 3. When bio-
markers of interest were compared with survival data, COX-2 was
the only biomarker that significantly impacted survival (expres-
sion associated with a hazards ratio of 0.06, p-value= 0.02).
SPARC (Poly) expression also showed trends toward survival
benefit (hazards ratio 0.15, p-value= 0.08).
DISCUSSION
Use of a commercial molecular profiling service can yield sig-
nificant information toward the understanding of biology and
treatment response of PM in patients with appendiceal or col-
orectal primaries. While concerns of mucinous disease interfering
with the test exist, we found that majority of the patients were able
to successfully undergo IHC evaluation of their samples, although
microarray could not be performed in some.
Previous studies have revealed that the phenotypes could be
clustered based on the gene expression profile. Levine et al.
reported gene expression profiling in 41 samples of patients with
PM of appendiceal and colorectal origin and showed that the two
groups were genomically different with impact on survival (8).
They identified 3 different phenotype clusters with the following
results: high risk colorectal cancer group with worst prognosis
(0% 5 years OS), high- and low-risk appendiceal subgroups (25
and 70% 10-year OS, respectively) (8).
The important role of BRAF/KRAS mutations in the tumor-
ogenesis pathway has been well elucidated (11, 23). Chan et al.
showed higher prevalence of BRAF or KRAS mutations (90%) in
serrated polyps with dysplasia compared to polyps without dyspla-
sia (54%), thereby suggesting a role in malignant transformation
(23). Some authors failed to show increased prevalence of BRAF
mutations in dysplastic specimens compared to non-dysplastic
serrated polyps and have argued that these mutations were asso-
ciated with serrated morphology rather than malignant transfor-
mation (11, 24). Mutations in KRAS have been associated with
metastatic colorectal cancer including peritoneal dissemination
FIGURE 1 | Mutational analysis of peritoneal metastases from colon and appendix primaries. WT, wild type; MUT, mutated.
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Table 3 | Unadjusted survival analysis stratified by biomarkers
identified in immunohistochemistry (IHC).
Biomarker Hazards ratio (95% CI) p-value
COX-2 0.06 (0.005–0.71) 0.02
RRM1 0.26 (0.04–1.57) 0.14
SPARC (Poly) 0.15 (0.02–1.3) 0.08
TS 1.00 1.00
COX-2, cyclooxygenase-2; RRM1, ribonucleotide reductase M1; SPARC,
secreted protein acidic cysteine-rich; TS, thymidylate synthase.
with implications for therapy (12, 25–27). Mutations in BRAF are
involved in sporadic colorectal tumorigenesis with proclivity to
develop PM, as well as poor survival outcomes compared to those
with KRAS mutations (13, 14).
In attempting to understand the profile of these tumors, the
high proportion of BRAF mutated tumors in the colorectal pri-
mary patients with PM is remarkable. Increasing evidence suggests
that the phenotype of BRAF mutated tumors presents with PM,
and aggressive biology, which is what we found in this small cohort
of patients (13, 14). Distinct in their genetic code, appendiceal
tumors did not express BRAF mutations, which confirm a distinct
origin from their counterparts, as suggested by other authors as
well (28, 29). Our study confirmed the high prevalence of KRAS
mutations (40%) in patients with appendiceal primaries, which are
similar to previous studies in which one found 45% with KRAS
mutations and another 91% with KRAS mutations among those
patients with appendiceal primaries with PM (30). We did not
encounter patients that exhibited both BRAF and KRAS mutations
simultaneously,which is also consistent with previous reports (15).
There is a possible survival benefit for patients with COX-2
expression especially in the setting of PM, which may lend cre-
dence to the use of aspirin or other NSAIDs in the management of
patients with peritoneal carcinomatosis. Although previous stud-
ies have identified the benefit of COX inhibitors in the treatment
and prevention of colorectal cancer, these data have not included
disease with PM (18, 19). Molecular studies on appendiceal adeno-
carcinoma also revealed increased expression of COX-2 but failed
to identify a prognostic value or therapeutic benefit with targeted
therapy (20). In light of this, more data would need to be collected
to analyze the effect COX inhibitors on PM with high COX-2
expression.
The purpose of molecular profiling is to guide therapies.
Appendiceal cancer is a rare primary and molecular profiling of
this histological subtype could be extremely useful when dealing
with high grade disease to determine potential molecular targets.
We were limited in our analysis due to our small sample size of
16 and also the insufficient sample for more than half of our
patients (56%) to have microarray analysis performed. In this
study, microarray analysis was limited by the amount of tumor
biopsied as well as by the mucinous content of the tumor. While
this sample may be too small and therefore underpowered to detect
potential targets for intervention, it does demonstrate the feasibil-
ity of this novel technique for patients with PM. It is noteworthy to
point out that we were able capture variations in the expression of
molecular markers and trends in survival benefit despite the small
size.
CONCLUSION
Immunohistochemistry and mutational analysis using commer-
cially available molecular profiling testing is feasible for patients
undergoing surgery for their PM, although mucin content might
interfere with microarray analysis. BRAF mutations and COX-2
expression deserve further investigation in the prognostication
and management of patients with colorectal and appendiceal
primaries.
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